Noncytotoxic Pyrrolobenzodiazepine–Ciprofloxacin Conjugate with Activity against Mycobacterium tuberculosis

• Pietro Picconi,
• Rose Jeeves,
• Christopher William Moon,
• Shirin Jamshidi,
• Kazi S. Nahar,
• Mark Laws,
• Joanna Bacon,
• Khondaker Miraz Rahman

Affiliations

Pietro Picconi

Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, King’s College London, London, U.K.

Rose Jeeves

TB Research Group, National Infection Service, Public Health England, Salisbury, Wiltshire, U.K.

Christopher William Moon

TB Research Group, National Infection Service, Public Health England, Salisbury, Wiltshire, U.K.

Shirin Jamshidi

Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, King’s College London, London, U.K.

Kazi S. Nahar

Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, King’s College London, London, U.K.

Mark Laws

Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, King’s College London, London, U.K.

Joanna Bacon

TB Research Group, National Infection Service, Public Health England, Salisbury, Wiltshire, U.K.

Khondaker Miraz Rahman

Institute of Pharmaceutical Science, School of Cancer and Pharmaceutical Science, King’s College London, London, U.K.